Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | Tuborg Boulevard 12 HELLERUP 2900 |
Tel: | N/A |
Website: | https://ascendispharma.dk |
IR: | See website |
Key People | ||
Jan Moller Mikkelsen President, Chief Executive Officer, Executive Director, Member of the Executive Board | Scott T. Smith Chief Financial Officer, Executive Vice President, Member of the Executive Board | Lotte Soenderbjerg Executive Vice President, Chief Administrative Officer |
Camilla Harder Hartvig Executive Vice President, Global Chief Commercial Officer | Flemming Steen Jensen Executive Vice President, Product Supply and Quality | Michael Wolff Jensen Executive Vice President, Chief Legal Officer |
Stina Singel Executive Vice President, Head of Clinical Development, Oncology | Kennett Sprogoee Executive Vice President, Head of Innovation and Research | Peter Rasmussen Principal Accounting Officer, Vice President - Finance |
Business Overview |
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark). |
Financial Overview |
For the three months ended 31 March 2024, Ascendis Pharma A/S (ADR) revenues increased from EUR33.6M to EUR95.9M. Net loss increased 18% to EUR131M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Finance expenses increase from EUR9.8M to EUR77.2M (expense), Finance income decrease of 92% to EUR3.6M (income). |